Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 10.19B +134.3% |
| Revenue (ttm) | 102.24M +133.8% |
| Net Income | -349.43M |
| EPS | -3.63 |
| Shares Out | 83.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,045,340 |
| Open | 127.00 |
| Previous Close | 122.51 |
| Day's Range | 117.74 - 127.74 |
| 52-Week Range | 55.66 - 130.05 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 139.83 (+14.05%) |
| Earnings Date | Oct 29, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $139.83, which is an increase of 14.05% from the latest price.
News
Kymera Therapeutics price target raised to $144 from $140 at Raymond James
Raymond James raised the firm’s price target on Kymera Therapeutics (KYMR) to $144 from $140 and keeps an Outperform rating on the shares. Kymera reported Q3 results and positive Phase…
Kymera Therapeutics Earnings Call Transcript: Q3 2026
KT-579 phase I showed deep IRF5 degradation, broad biomarker effects and placebo-like safety, supporting a lupus phase Ib study. KT-621 AD phase IIb results are expected by year-end; ~$1.6B in cash and investments supports runway into 2029.
Kymera Therapeutics Earnings release: Q3 2026
Kymera Therapeutics released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Kymera Therapeutics Quarterly report: Q3 2026
Kymera Therapeutics has published its Q3 2026 quarterly earnings report on October 29, 2026.
Kymera Therapeutics Slides: Q3 2026
Kymera Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Kymera Therapeutics Slides: Company presentation
Kymera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
Kymera Therapeutics reports Q3 EPS ($1.32), consensus ($1.27)
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology,” said Nello Mainolfi, Founder, Preside...
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics price target raised to $146 from $135 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Kymera Therapeutics (KYMR) to $146 from $135 and keeps an Overweight rating on the shares.
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Thomas Deal initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and $140 price target Kymera’s pipeline is led by KT-621 with “broad potential” in Type…
Citi adds ‘upside 90-day catalyst watch’ on Kymera Therapeutics
Citi analyst Geoff Meacham placed Kymera Therapeutics (KYMR) on “upside 90-day catalyst watch” after upping the stock’s price target to $150 from $135. The firm sees a favorable risk/reward into…
Kymera Therapeutics price target raised to $150 from $135 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Kymera Therapeutics (KYMR) to $150 from $135 and keeps a Buy rating on the shares. The firm sees an attractive…
JPMorgan SMid biotech analysts hold an analyst/industry conference call
SMid Biotechnology Analysts Cheng and Medeiros discuss their view on Kymera Therapeutics’s (KYMR) STATS readout in atopic dermatitis on an Analyst/Industry conference call on October 1 at 3 pm. Webcas...
Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
JPMorgan analyst Brian Cheng placed Kymera Therapeutics (KYMR) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $140 price target The firm believes the Phase…
Kymera Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
The forum highlighted rapid progress in targeted protein degradation, with KT-621's phase II-B readout accelerated due to strong demand and robust trial design. Expansion into pediatric and multiple type 2 indications is planned, and the IRF5 program is advancing toward clinical proof-of-concept.
Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. Goldman resumed coverage of the biotechnology sector, saying the group has conti...
Kymera Therapeutics price target raised to $152 from $132 at Stifel
Stifel raised the firm’s price target on Kymera Therapeutics (KYMR) to $152 from $132 and keeps a Buy rating on the shares. Topline data from the Phase 2b BROADEN2 study…
Kymera Therapeutics management to meet with Piper Sandler
Meeting to be held on September 21 hosted by Piper Sandler.
Kymera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted advances in targeted protein degradation, with a focus on immunology and key programs like KT-621 (STAT6 degrader) and KT-579 (IRF5 degrader). KT-621 shows strong clinical promise for atopic dermatitis, aiming to expand the market for oral therapies, while robust trial design and safety monitoring support future development.
Kymera Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted advances in targeted protein degradation, with lead programs STAT6 and IRF5 progressing through clinical stages. STAT6 showed strong efficacy and safety in atopic dermatitis, with phase IIb data expected by year-end and phase III studies planned.
Kymera Therapeutics price target raised to $144 from $123 at BofA
BofA raised the firm’s price target on Kymera Therapeutics (KYMR) to $144 from $123 and keeps a Buy rating on the shares after having hosted CEO Nello Mainolfi and CFO…
Kymera Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The discussion highlighted a strategic focus on immunology, with a robust pipeline targeting type 2 inflammation and comorbidities. Key programs, STAT6 and IRF5, are advancing rapidly, with major data readouts expected this year. Oral therapies are positioned to transform treatment paradigms by expanding access and convenience.
Wolfe upgrades Kymera Therapeutics to Outperform on potential upside
As previously reported, Wolfe Research upgraded Kymera Therapeutics (KYMR) to Outperform from Peer Perform with an $180 price target After engineering hypothetical placebo data, the firm sees two pote...